Patients and calibration. Fifty-four patients with untreated PTCL enrolled in the treatment study and were screened to determine whether baseline FFPE and/or serum samples were available. Thirty-four patients had a dominant T-cell receptor rearrangement identified from FFPE or serum samples, and they comprised the study cohort for the correlative analysis of circulating tumor DNA.